🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Revascularization of Single Vesrus Multiple Infrapopliteal Vessels in Chronic Limb Threatening Ischemia

RecruitingNAAges 40 Years - anyAllSohag University
NCT07068789 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This interventional prospective study aims to assess the effectiveness of single vessel versus multiple vessel infrapopliteal angioplasty in patients with chronic threatening limb ischemia . The study compares limb salvage rates and clinical outcomes across two groups over a defined follow up period

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. patients aged 40 years or older 2. patients with Rutherford category "4" and "5" 3. patients with angiographic evidence of infrapopliteal vessel occlusive disease - Exclusion Criteria: 1. patients who refuse to participate in the study 2. patients with isolated proximal arterial disease (e.g SFA or popliteal ) without infrapopliteal involvement 3. patients who develop acute thrombosis , flow limiting dissection or perforation in the infrapopliteal arteries during intervention -
💊

What it tests

  • balloon angioplasty
📍

Where

1 site
Faculty of Medicine of Sohag
Sohag, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy